The expression of the inhibitory immune checkpoints PD-L1 and VISTA may explain the poor responsiveness of prostate cancer patients to CTLA-4 blockade and supports the design of a combination therapy targeting both molecules. This evidence concerns the gene VSIR and prostate carcinoma.